null

null

null

null

null

null

null

null

null

4.58x Total Debt / Equity (High leverage)

Low direct sensitivity; debt-light balance sheet (~$0 long-term debt), but rising rates increase burn cost on cash reserves and tighten biotech equity financing windows

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) US-EU gene therapy vector manufacturing (lentiviral); 2) Single-source GMP-grade T-cell processing reagents concentrated in US/UK suppliers

Revenue primarily USD-denominated via US partnerships; modest GBP exposure from UK operations; minimal sovereign devaluation risk given limited ex-US commercial sales

Dual US-UK footprint; GBP/USD fluctuation is primary FX risk; EU operations emerging post-afami approval; limited EM currency exposure currently

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High; Novatek/WuXi-type CDMO relationships for TCR-T cell manufacturing represent non-substitutable GMP capacity; switching cost estimated 18-24 months and $50M+

Cloud disruption moderate; clinical/manufacturing data systems could face 30-day migration risk but core IP and regulatory filings are not cloud-dependent

Biopharmaceutical drug developer transitioning to commercial-stage; secondary model includes partnership/licensing milestones and royalties from GSK collaboration

Moderate API coupling risk; reliance on proprietary TCR library databases and Immunocore/GSK collaborative platforms; internal switching cost high but not externally API-driven

Low Howey risk; revenue model is drug sales and licensing milestones — clearly a biopharma commercial model, not an investment contract or token scheme

Very High

Moderate GDPR exposure via UK/EU clinical trial patient data; CCPA exposure limited; clinical data governance frameworks generally in place but post-Brexit UK GDPR adds compliance layer

Low; niche orphan/rare cancer cell therapy market; no dominant market share; partnerships with GSK reviewed but not flagged; pricing scrutiny risk higher than structural antitrust risk

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional/milestone-based currently; afami-cel commercial launch in synovial sarcoma began 2024; subscription-type recurring revenue near zero; milestone payments episodic

Drug product sales (afami-cel at ~$700K+ per patient course) plus partnership milestones/royalties; ultra-high ASP, low volume model

Single-course curative pricing ~$700K-$900K per patient; reimbursement-dependent; stress scenario: payer pushback or CMS negotiation could compress net price 20-40%

Moderate-high in short term given orphan designation and no direct competitors in synovial sarcoma; long-term pricing power contingent on outcome data and payer contracts

Target gross margin 60-75% at scale; currently negative due to low volume and high COGS from autologous manufacturing; break-even requires ~150-200 annual patient treatments

No free-rider risk; one-time curative therapy eliminates repeat-purchase model; patient pool is finite and disease-defined; key risk is market exhaustion not churn

Headcount-sublinear at commercial scale; manufacturing scale-up is capital- not headcount-intensive; doubling revenue does not require doubling staff; estimated 1.3x headcount for 2x revenue

Marginal cost dominated by GMP manufacturing per-patient COGS (~$200K-$400K estimated); scale economies achievable via process optimization and centralized manufacturing hubs

Not applicable; company does not operate a franchise network

At 10x scale (~1,500 patients/year): CAC remains low as sarcoma oncologists are a concentrated prescriber base (~500 US centers); marketing efficiency improves; COGS per unit declines

Weak direct network effects; proprietary TCR library expands with each patient (data network effect), but commercial product has no traditional platform network effect

-27.3% Return on Assets (Negative equity)

Tier 2 resilience; rare/terminal cancer therapies maintain demand in recession but reimbursement tightening and hospital budget cuts can delay treatment authorization

Specialty oncology centers and academic medical centers treating synovial sarcoma and solid tumor patients; ~50-100 high-volume US sarcoma centers represent 80%+ of near-term volume

Collaborative pharma partners (GSK for legacy programs); potential future payer/IDN contracts; EU oncology centers as EMA approval pathway progresses

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.5% CapEx / Revenue (Low-CapEx Asset-Light)

0001621227

ADAPY